Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Vingerhoets, J, Calvez, V, Flandre, P, Marcelin, A-G, Ceccherini-Silberstein, F, Perno, C-F, Mercedes Santoro, M, Bateson, R, Nelson, M, Cozzi-Lepri, A, Grarup, J, Lundgren, J, Incardona, F, Kaiser, R, Sonnerborg, A, Clotet, B, Paredes, R, Günthard, HF, Ledergerber, B, Hoogstoel, A, Nijs, S, Tambuyzer, L, Lavreys, L, Opsomer, M & Etravirine Cohort Study Group 2015, 'Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data' HIV Medicine, bind 16, nr. 5, s. 297-306. https://doi.org/10.1111/hiv.12218

APA

Vingerhoets, J., Calvez, V., Flandre, P., Marcelin, A-G., Ceccherini-Silberstein, F., Perno, C-F., ... Etravirine Cohort Study Group (2015). Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine, 16(5), 297-306. https://doi.org/10.1111/hiv.12218

CBE

Vingerhoets J, Calvez V, Flandre P, Marcelin A-G, Ceccherini-Silberstein F, Perno C-F, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard HF, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M, Etravirine Cohort Study Group. 2015. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine. 16(5):297-306. https://doi.org/10.1111/hiv.12218

MLA

Vancouver

Author

Vingerhoets, J ; Calvez, V ; Flandre, P ; Marcelin, A-G ; Ceccherini-Silberstein, F ; Perno, C-F ; Mercedes Santoro, M ; Bateson, R ; Nelson, M ; Cozzi-Lepri, A ; Grarup, J ; Lundgren, J ; Incardona, F ; Kaiser, R ; Sonnerborg, A ; Clotet, B ; Paredes, R ; Günthard, H F ; Ledergerber, B ; Hoogstoel, A ; Nijs, S ; Tambuyzer, L ; Lavreys, L ; Opsomer, M ; Etravirine Cohort Study Group. / Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients : an observational study using pooled European cohort data. I: HIV Medicine. 2015 ; Bind 16, Nr. 5. s. 297-306.

Bibtex

@article{cc92cac06d3f4839bfa52bf443afa0c2,
title = "Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data",
abstract = "OBJECTIVES: This observational study in antiretroviral treatment-experienced, HIV-1-infected adults explored the efficacy of etravirine plus darunavir/ritonavir (DRV group; n = 999) vs. etravirine plus an alternative boosted protease inhibitor (other PI group; n = 116) using pooled European cohort data.METHODS: Two international (EuroSIDA; EUResist Network) and five national (France, Italy, Spain, Switzerland and UK) cohorts provided data (collected in 2007-2012). Stratum-adjusted (for confounding factors) Mantel-Haenszel differences in virological responses (viral load < 50 HIV-1 RNA copies/mL) and odds ratios (ORs) with 95{\%} confidence intervals (CIs) were derived.RESULTS: Baseline characteristics were balanced between groups except for previous use of antiretrovirals (≥ 10: 63{\%} in the DRV group vs. 49{\%} in the other PI group), including previous use of at least three PIs (64{\%} vs. 53{\%}, respectively) and mean number of PI resistance mutations (2.3 vs. 1.9, respectively). Week 24 responses were 73{\%} vs. 75{\%} (observed) and 49{\%} vs. 43{\%} (missing = failure), respectively. Week 48 responses were 75{\%} vs. 73{\%} and 32{\%} vs. 30{\%}, respectively. All 95{\%} CIs around unadjusted and adjusted differences encompassed 0 (difference in responses) or 1 (ORs). While ORs by cohort indicated heterogeneity in response, for pooled data the difference between unadjusted and adjusted for cohort ORs was small.CONCLUSIONS: These data do not indicate a difference in response between the DRV and other PI groups, although caution should be applied given the small size of the other PI group and the lack of randomization. This suggests that the efficacy and virology results from DUET can be extrapolated to a regimen of etravirine with a boosted PI other than darunavir/ritonavir.",
keywords = "CD4 Lymphocyte Count, Drug Therapy, Combination, Female, France, Great Britain, HIV Infections, HIV Protease Inhibitors, Humans, Italy, Male, Meta-Analysis as Topic, Middle Aged, Odds Ratio, Pyridazines, Ritonavir, Spain, Sulfonamides, Switzerland, Viral Load",
author = "J Vingerhoets and V Calvez and P Flandre and A-G Marcelin and F Ceccherini-Silberstein and C-F Perno and {Mercedes Santoro}, M and R Bateson and M Nelson and A Cozzi-Lepri and J Grarup and J Lundgren and F Incardona and R Kaiser and A Sonnerborg and B Clotet and R Paredes and G{\"u}nthard, {H F} and B Ledergerber and A Hoogstoel and S Nijs and L Tambuyzer and L Lavreys and M Opsomer and {Etravirine Cohort Study Group}",
note = "{\circledC} 2015 British HIV Association.",
year = "2015",
month = "5",
doi = "10.1111/hiv.12218",
language = "English",
volume = "16",
pages = "297--306",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients

T2 - an observational study using pooled European cohort data

AU - Vingerhoets, J

AU - Calvez, V

AU - Flandre, P

AU - Marcelin, A-G

AU - Ceccherini-Silberstein, F

AU - Perno, C-F

AU - Mercedes Santoro, M

AU - Bateson, R

AU - Nelson, M

AU - Cozzi-Lepri, A

AU - Grarup, J

AU - Lundgren, J

AU - Incardona, F

AU - Kaiser, R

AU - Sonnerborg, A

AU - Clotet, B

AU - Paredes, R

AU - Günthard, H F

AU - Ledergerber, B

AU - Hoogstoel, A

AU - Nijs, S

AU - Tambuyzer, L

AU - Lavreys, L

AU - Opsomer, M

AU - Etravirine Cohort Study Group

N1 - © 2015 British HIV Association.

PY - 2015/5

Y1 - 2015/5

N2 - OBJECTIVES: This observational study in antiretroviral treatment-experienced, HIV-1-infected adults explored the efficacy of etravirine plus darunavir/ritonavir (DRV group; n = 999) vs. etravirine plus an alternative boosted protease inhibitor (other PI group; n = 116) using pooled European cohort data.METHODS: Two international (EuroSIDA; EUResist Network) and five national (France, Italy, Spain, Switzerland and UK) cohorts provided data (collected in 2007-2012). Stratum-adjusted (for confounding factors) Mantel-Haenszel differences in virological responses (viral load < 50 HIV-1 RNA copies/mL) and odds ratios (ORs) with 95% confidence intervals (CIs) were derived.RESULTS: Baseline characteristics were balanced between groups except for previous use of antiretrovirals (≥ 10: 63% in the DRV group vs. 49% in the other PI group), including previous use of at least three PIs (64% vs. 53%, respectively) and mean number of PI resistance mutations (2.3 vs. 1.9, respectively). Week 24 responses were 73% vs. 75% (observed) and 49% vs. 43% (missing = failure), respectively. Week 48 responses were 75% vs. 73% and 32% vs. 30%, respectively. All 95% CIs around unadjusted and adjusted differences encompassed 0 (difference in responses) or 1 (ORs). While ORs by cohort indicated heterogeneity in response, for pooled data the difference between unadjusted and adjusted for cohort ORs was small.CONCLUSIONS: These data do not indicate a difference in response between the DRV and other PI groups, although caution should be applied given the small size of the other PI group and the lack of randomization. This suggests that the efficacy and virology results from DUET can be extrapolated to a regimen of etravirine with a boosted PI other than darunavir/ritonavir.

AB - OBJECTIVES: This observational study in antiretroviral treatment-experienced, HIV-1-infected adults explored the efficacy of etravirine plus darunavir/ritonavir (DRV group; n = 999) vs. etravirine plus an alternative boosted protease inhibitor (other PI group; n = 116) using pooled European cohort data.METHODS: Two international (EuroSIDA; EUResist Network) and five national (France, Italy, Spain, Switzerland and UK) cohorts provided data (collected in 2007-2012). Stratum-adjusted (for confounding factors) Mantel-Haenszel differences in virological responses (viral load < 50 HIV-1 RNA copies/mL) and odds ratios (ORs) with 95% confidence intervals (CIs) were derived.RESULTS: Baseline characteristics were balanced between groups except for previous use of antiretrovirals (≥ 10: 63% in the DRV group vs. 49% in the other PI group), including previous use of at least three PIs (64% vs. 53%, respectively) and mean number of PI resistance mutations (2.3 vs. 1.9, respectively). Week 24 responses were 73% vs. 75% (observed) and 49% vs. 43% (missing = failure), respectively. Week 48 responses were 75% vs. 73% and 32% vs. 30%, respectively. All 95% CIs around unadjusted and adjusted differences encompassed 0 (difference in responses) or 1 (ORs). While ORs by cohort indicated heterogeneity in response, for pooled data the difference between unadjusted and adjusted for cohort ORs was small.CONCLUSIONS: These data do not indicate a difference in response between the DRV and other PI groups, although caution should be applied given the small size of the other PI group and the lack of randomization. This suggests that the efficacy and virology results from DUET can be extrapolated to a regimen of etravirine with a boosted PI other than darunavir/ritonavir.

KW - CD4 Lymphocyte Count

KW - Drug Therapy, Combination

KW - Female

KW - France

KW - Great Britain

KW - HIV Infections

KW - HIV Protease Inhibitors

KW - Humans

KW - Italy

KW - Male

KW - Meta-Analysis as Topic

KW - Middle Aged

KW - Odds Ratio

KW - Pyridazines

KW - Ritonavir

KW - Spain

KW - Sulfonamides

KW - Switzerland

KW - Viral Load

U2 - 10.1111/hiv.12218

DO - 10.1111/hiv.12218

M3 - Journal article

VL - 16

SP - 297

EP - 306

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 5

ER -

ID: 45839596